In this series we draw attention to medicines that have entered the European market with an entirely new mechanism of action. Publication is not to be confused with endorsement of use in clinical practice. Copyright to the images belongs to Leiden University, but use of the images (also available at http://coo.lumc.nl/trc) is free.
Rilonacept and canakinumab
Article first published online: 11 APR 2011
British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society No claim to original US government works
British Journal of Clinical Pharmacology
Special Issue: Drug allergy: themed section
Volume 71, Issue 5, pages 639–641, May 2011
How to Cite
Dubois, E. A., Rissmann, R. and Cohen, A. F. (2011), Rilonacept and canakinumab. British Journal of Clinical Pharmacology, 71: 639–641. doi: 10.1111/j.1365-2125.2011.03958.x
- Issue published online: 11 APR 2011
- Article first published online: 11 APR 2011
- Accepted manuscript online: 7 MAR 2011 02:04AM EST
Two new orphan medicines, rilonacept [1, 2] (Regeneron®) and canakinumab [3, 4] (Ilaris®), are indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS). CAPS occur in a group of rare, inherited, inflammatory diseases where patients have a mutation in the NLRP3 (nucleotide-binding domain, leucine-rich family, pyrin domain-containing-3) gene encoding for cryopyrin, which is a regulator in the acute immune reaction. Both familial cold auto-inflammatory syndrome and Muckle–Wells syndrome belong to the CAPS group. Additionally, canakinumab may be used to treat other CAPS such as neonatal-onset multisystem inflammatory disease and familial cold urticaria. The indications for both drugs might be extended in future. Currently, these two drugs are being evaluated in more common diseases including rheumatoid arthritis and systemic-onset juvenile idiopathic arthritis [5, 6].
The pathophysiology underlying CAPS is characterized by overstimulation of the regulatory system of thepro-inflammatory cytokine interleukin-1β (Il-1β). The synthesis and release of Il-1β requires two distinct signals which are normally initiated by damage-associated molecular patterns, either pathogen-associated molecular patterns, e.g. bacterial RNA or lipopolysaccharides, or endogenous irritants, e.g. uric acid or heat shock proteins. One signal leads to synthesis of pro-Il-1β and components of the protein complex inflammasome NLRP3/cryopyrin. A second signal leads to the assembly of the inflammasome and activation of caspase-1. Active Il-1β is released from pro-Il-1β by caspase-1 (Figure 1).
In order to exert its pro-inflammatory actions, Il-1β must bind two receptors, the interleukin 1 receptor (Il-1-R1) and an accessory protein (Il-1-RAcP). These receptors form a complex at the membrane necessary for signal transduction.
Rilonacept and canakinumab each work by trapping Il-1β before it binds its receptor complex, preventing the pro-inflammatory effects that cause the symptoms of CAPS (Figure 2).
Rilonacept consists of the extracellular domains of the Il-1-RAcP and the Il-1-R1 fused to the Fc portion of human IgG1. It binds Il-1β and Il-1α with high affinity and potently inhibits Il-1 activity. It is administered subcutaneously beginning with a loading dose followed by a weekly injection of half the loading dose.
Canakinumab is a specific human monoclonal IgG1 antibody targeted against Il-1β. This antibody has no cross-reactivity with Il-1α nor with the Il-1-R1 receptor. Canakinumab is also injected subcutaneously, but less often than rilonacept (once every 8 weeks).
In general, the adverse effects of rilonacept and canakinumab are similar and have been mild. By blocking Il-1 actions, either of these drugs could interfere with the immune response. The most common adverse effects (>10% of treated patients) are reactions at the injection site, inflammation of the upper respiratory tract or sinuses and headache. CAPS patients suffering from severe, active infection should not be treated with either rilonacept or canakinumab.